| Antibiotic
therapies |
| CRS3123, 5
|
I |
National Institute of Allergy and Infectious
Diseases (NIAID) |
methionyl-tRNA synthetase inhibitor |
(59) |
| NVB302, 6
|
I |
Novacta
Biosystems Limited |
lantibiotic |
(60) |
| SMT19969, 7
|
II |
Summit Corporation Plc./Wellcome Trust |
bis-benzimidazole |
(63) |
| LFF571, 8
|
II |
Novartis Pharmaceuticals |
4-aminothiazolyl macrocycle |
(62) |
| cadazolid, 9
|
III |
Actelion |
quinolonyloxazolidinone |
(64) |
| ramoplanin, 10
|
II (previously
completed phase III) |
Nanotherapeutics, Inc. |
lipoglycodepsipeptide |
(65) |
| rifaximin, 3
|
III |
Salix Pharmaceuticals |
rifamycin |
(166) |
| CB-183,315, 11
|
III |
Cubist Pharmaceuticals |
lipopeptide |
(67, 68) |
| nitazoxanide, 13
|
III |
VA Medical Center, Houston/Baylor
College of Medicine |
nitrothiazolide |
(70) |
| Nonantibiotic
therapies |
| IC84 |
I |
Valneva Austria GmbH |
vaccine |
(72) |
| frozen encapsulated FMT |
I |
Massachusetts
General Hospital |
microbiota restoration |
(167) |
| frozen FMT |
I |
Massachusetts General
Hospital |
microbiota restoration |
(168) |
| defined FMT |
I |
Baylor College of Medicine/Michael
Debakey Veterans Affairs
Medical Center |
microbiota restoration |
(169) |
| PF-06425090 |
II |
Pfizer |
vaccine |
(170) |
| VP20621 |
II |
Shire |
nontoxigenic C. difficile
|
(75) |
| GS-CDA1, MDX-1388 |
II |
University of Massachusetts,
Worcester/Medarex |
human monoclonal antibodies |
(171) |
| FMT |
II |
NorthShore University
HealthSystem |
microbiota restoration |
(172) |
| FMT in pediatric patients |
II |
MemorialCare
Health System |
microbiota restoration |
(173) |
| FMT |
II |
Colleen Kelly, The Miriam Hospital |
microbiota restoration |
(174) |
| FMT by colonoscopy |
II |
Catholic University
of the Sacred Heart |
microbiota restoration |
(175) |
| RBX2660 |
II |
Rebiotix Inc. |
microbiota restoration |
(80) |
| tolevamer (GT267-004) |
III |
Genzyme |
toxin binder |
(73) |
| MK-3415, MK-6072, and MK-3415A |
III |
Merck |
human monoclonal antibodies |
(74) |
| ACAM-CDIFF |
III |
Sanofi-Pasteur |
vaccine |
(71) |
| Bio-K+ CL-1285 |
III |
Bio-K Plus International Inc. |
microbiota restoration |
(79) |
| FMT by capsule versus colonoscopy |
II/III |
University of Alberta/University of Calgary |
microbiota
restoration |
(176) |
